Vascodagama Online Journal

Dystrophic Epidermolysis Bullosa Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Dystrophic Epidermolysis Bullosa Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight

February 07
01:44 2023
Dystrophic Epidermolysis Bullosa Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight
DelveInsight’s, “Dystrophic Epidermolysis Bullosa – Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight’s, “Dystrophic Epidermolysis Bullosa – Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s Dystrophic Epidermolysis Bullosa Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Dystrophic Epidermolysis Bullosa therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dystrophic Epidermolysis Bullosa pipeline domain.

 

Key Takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report

  • Over 15+ Dystrophic Epidermolysis Bullosa pipeline therapies are in various stages of development, and their anticipated acceptance in the Dystrophic Epidermolysis Bullosa market would significantly increase market revenue. 
  • Leading Dystrophic Epidermolysis Bullosa companies developing novel drug candidates to improve the Dystrophic Epidermolysis Bullosa treatment landscape include Phoenix Tissue Repair, Castle Creek Biosciences, and others.
  • Promising Dystrophic Epidermolysis Bullosa pipeline therapies in various stages of development include PTR-01, FCX-007, and others.

 

Dystrophic Epidermolysis Bullosa Overview

Dystrophic epidermolysis bullosa is one of the major forms of a group of conditions called epidermolysis bullosa. Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. 

The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. 

Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems. The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems.

 

Request for a sample report to know more about Dystrophic Epidermolysis Bullosa treatment algorithm and diagnosis.

 

Dystrophic Epidermolysis Bullosa Pipeline Analysis: Drug Profile

PTR-01: Phoenix Tissue Repair

Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.

 

Discover more about the emerging Dystrophic Epidermolysis Bullosa drugs @ Dystrophic Epidermolysis Bullosa Treatment Drugs

 

Dystrophic Epidermolysis Bullosa Key Companies

  • Phoenix Tissue Repair
  • Castle Creek Biosciences

 

Dystrophic Epidermolysis Bullosa Pipeline Therapies

  • PTR-01
  • FCX-007

 

Dystrophic Epidermolysis Bullosa Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

 

Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report 

  • Coverage: Global 
  • Key Dystrophic Epidermolysis Bullosa Companies: Phoenix Tissue Repair, Castle Creek Biosciences, and others
  • Key Dystrophic Epidermolysis Bullosa Pipeline Therapies: PTR-01, FCX-007, and others

 

Find out more about the Dystrophic Epidermolysis Bullosa treatment options in development @ Dystrophic Epidermolysis Bullosa Clinical Trials

 

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

 

Other Trending Reports:

  • Asthma Diagnostic Devices Market
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market
  • Airway Management Devices Market
  • Cough Assist Devices Market
  • Pulse Oximeters Market
  • Hemodialysis Catheter Devices Market
  • Chronic Spontaneous Urticaria Market 
  • Gender Dysphoria Market
  • Germany Healthcare Outlook
  • Biopsy Devices Pipeline Insight
  • Bacterial Conjunctivitis Market
  • Infliximab Biosimilar Insight
  • Eosinophilic Asthma Market
  • Cushing Syndrome Market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

 

Contact Us

Kritika Rehani

[email protected] 

+1(919)321-6187 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories